尿素サイクル障害治療の世界市場レポート 2025年

尿素サイクル障害治療の市場規模は、今後数年間で安定した成長が見込まれます。2029年には16億5,000万米ドルに成長し、CAGRは4.5%となります。予測期間の成長は、酵素補充療法の進歩、新生児スクリーニングプログラムの拡大、調査協力の増加、治療選択肢の拡大、遠隔医療、遠隔診療などに起因します。予測期間における主な動向としては、高度な遺伝子編集技術、啓発・擁護活動、再生医療アプローチ、長期安全性・有効性研究、個別化栄養療法などが挙げられます。

尿素サイクル障害の有病率の増加が、今後の尿素サイクル障害治療市場の成長を牽引すると予測されています。尿素サイクル障害とは、肝臓による血流からのアンモニア除去に不可欠な酵素またはトランスポーター分子のいずれかの欠陥に起因する遺伝性の代謝疾患を指します。これらの疾患の増加は、主に遺伝的要因によるものです。アンモニアの蓄積が尿素サイクル障害（UCD）と特定された場合、その悪影響を軽減するために、食事管理、薬物療法、モニタリングを含むオーダーメイドの治療アプローチを確立することができます。例えば、2023年4月、米国を拠点とする医学教育リソースであるStatPearls Publishing LLCのデータによると、オルニチントランスカルバミラーゼ欠損症による尿素サイクル障害の有病率は14万人に1人です。さらに、ドイツを拠点とするデジタル医学教育プラットフォームであるLecturioによると、2022年9月、尿素サイクル障害（UCD）は、世界では約35,000人の出生に1人、米国では8,200人の出生に1人の割合で発生し、その結果、米国では年間およそ113人、欧州ではおよそ149人が新たに発症することになります。したがって、尿素サイクル障害の有病率の上昇が尿素サイクル障害治療市場の成長を促進しています。

慢性腎臓病患者の増加は、尿素サイクル障害治療市場の拡大に寄与すると予想されます。慢性腎臓病（CKD）は、時間の経過とともに腎機能が徐々に低下することを特徴とし、代謝性廃棄物、特に腎機能低下による尿素値の上昇を管理するために尿素サイクル障害治療を利用します。2023年11月現在、推定720万人が慢性腎臓病（CKD）のステージ1～5にあると考えられており、英国では約350万人がCKDの後期段階（ステージ3～5）にあり、症状のコントロールが徐々に難しくなっています。したがって、慢性腎臓病患者数の増加が尿素サイクル障害治療市場成長の原動力となっています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、コロナ禍、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界尿素サイクル障害治療PESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界の尿素サイクル障害治療市場：成長率分析
• 世界の尿素サイクル障害治療市場の実績：規模と成長, 2019-2024
• 世界の尿素サイクル障害治療市場の予測：規模と成長, 2024-2029, 2034F
• 世界尿素サイクル障害治療総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の尿素サイクル障害治療市場治療別、実績と予測, 2019-2024, 2024-2029F, 2034F
• アミノ酸サプリメント
• フェニル酪酸ナトリウム
• グリセロールフェニルブチレート
• 安息香酸ナトリウム
• その他の治療法
• 世界の尿素サイクル障害治療市場酵素欠乏症による、実績と予測, 2019-2024, 2024-2029F, 2034F
• オルニチントランスカルバミラーゼ（OTC）
• アルギニノコハク酸合成酵素（AS）
• アルギナーゼ（AG）
• アルギニノコハク酸リアーゼ（AL）
• カルバモイルリン酸合成酵素（CPS1）
• 世界の尿素サイクル障害治療市場：投与経路別、実績と予測, 2019-2024, 2024-2029F, 2034F
• オーラル
• 注射剤
• 世界の尿素サイクル障害治療市場：流通チャネル別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院薬局
• 小売薬局
• オンライン薬局
• 世界の尿素サイクル障害治療市場アミノ酸サプリメントの種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• アルギニンサプリメント
• シトルリンサプリメント
• その他の必須アミノ酸
• 世界の尿素サイクル障害治療市場フェニル酪酸ナトリウムのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 粉末状
• タブレットフォーム
• 世界の尿素サイクル障害治療市場、グリセロールフェニルブチレートのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 経口溶液
• その他の形式
• 世界の尿素サイクル障害治療市場、安息香酸ナトリウムの種類別のサブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 点滴液
• 経口製剤
• 世界の尿素サイクル障害治療市場、その他の治療法のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 肝臓移植
• 食生活の変更
• 酵素補充療法
• その他の支持療法

第7章 地域別・国別分析

• 世界の尿素サイクル障害治療市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の尿素サイクル障害治療市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 尿素サイクル障害治療市場：競合情勢
• 尿素サイクル障害治療市場：企業プロファイル
  • Bausch Health Companies Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Recordati Rare Diseases Overview, Products and Services, Strategy and Financial Analysis
  • Eurocept Pharmaceuticals Holding（Lucane Pharma SA）Overview, Products and Services, Strategy and Financial Analysis
  • Acer Therapeutics Overview, Products and Services, Strategy and Financial Analysis
  • Ultragenyx Pharmaceutical Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Aeglea BioTherapeutics
• Arcturus Therapeutics, Inc.
• Orpharma Pty Ltd.
• Selecta Biosciences, Inc.
• Abbott Laboratories
• Mead Johnson & Company, LLC
• Horizon Therapeutics Plc
• Nestle S.A.
• Danone S.A.
• Biophone
• Relief Therapeutics Holding AG
• TheraTriage
• Genomatica
• Protalix BioTherapeutics
• Erytech Pharma

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 尿素サイクル障害治療市場2029：新たな機会を提供する国
• 尿素サイクル障害治療市場2029：新たな機会を提供するセグメント
• 尿素サイクル障害治療市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Urea cycle disorder treatment involves managing rare genetic diseases in which the body lacks the necessary enzymes to break down ammonia, leading to its accumulation and potential toxicity. The primary goal of urea cycle disorder treatment is to reduce blood ammonia levels.

The main types of treatment for urea cycle disorders include amino acid supplements, sodium phenylbutyrate, glycerol phenylbutyrate, sodium benzoate, and others. Amino acid supplements contain one or more of the nine essential amino acids that the body requires but cannot produce independently. Specific types of enzyme deficiencies are addressed, such as OTC (ornithine transcarbamylase), AS (argininosuccinate synthetase) for citrullinemia, AG (arginase), AL (argininosuccinate lyase), and CPS1 (carbamoyl phosphate synthase). These treatments can be administered orally and through injections, and they are distributed through various channels, including hospital pharmacies, retail pharmacies, and online pharmacies.

The urea cycle disorders treatment market research report is one of a series of new reports from The Business Research Company that provides urea cycle disorders treatment market statistics, including urea cycle disorders treatment industry global market size, regional shares, competitors with a urea cycle disorders treatment market share, detailed urea cycle disorders treatment market segments, market trends and opportunities, and any further data you may need to thrive in the urea cycle disorders treatment industry. This urea cycle disorders treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The urea cycle disorders treatment market size has grown steadily in recent years. It will grow from $1.33 billion in 2024 to $1.39 billion in 2025 at a compound annual growth rate (CAGR) of 4.0%. The growth in the historic period can be attributed to awareness and education, improvements in newborn screening, emergence of patient support networks, standard of care guidelines

The urea cycle disorders treatment market size is expected to see steady growth in the next few years. It will grow to $1.65 billion in 2029 at a compound annual growth rate (CAGR) of 4.5%. The growth in the forecast period can be attributed to advancements in enzyme replacement therapy, expanded newborn screening programs, increased collaboration in research, expansion of therapeutic options, telemedicine and remote care. Major trends in the forecast period include advanced gene editing techniques, awareness and advocacy initiatives, regenerative medicine approaches, long-term safety and efficacy studies, and personalized nutritional therapies.

The increasing prevalence of urea cycle disorders is projected to drive the growth of the urea cycle disorders treatment market in the future. Urea cycle disorders refer to metabolic conditions that are inherited and result from defects in one of the enzymes or transporter molecules essential for the liver's removal of ammonia from the bloodstream. The rise in these disorders is primarily attributed to genetic factors. When ammonia accumulation is identified as a urea cycle disorder (UCD), a tailored treatment approach involving dietary management, medication, and monitoring can be established to mitigate its adverse effects. For example, in April 2023, data from StatPearls Publishing LLC, a US-based medical education resource, indicated that the prevalence of urea cycle disorders due to ornithine transcarbamylase deficiency is 1 in 140,000 individuals. Additionally, in September 2022, according to Lecturio, a Germany-based digital medical education platform, Urea cycle disorders (UCDs) occur in about 1 in every 35,000 live births globally and 1 in 8,200 live births in the United States, resulting in an annual incidence of roughly 113 new cases in the U.S. and around 149 in Europe. Therefore, the rising prevalence of urea cycle disorders is fueling the growth of the urea cycle disorders treatment market.

The increasing number of chronic kidney disorder cases is expected to contribute to the expansion of the urea cycle disorders treatment market. Chronic kidney disease (CKD), characterized by the gradual loss of kidney function over time, utilizes urea cycle disorder treatment to manage metabolic waste, especially elevated urea levels due to impaired kidney function. As of November 2023, an estimated 7.2 million individuals are believed to have chronic kidney disease (CKD) stages 1-5, with approximately 3.5 million people in the UK experiencing the later stages of CKD (stages 3-5), where symptoms become progressively challenging to control. Hence, the growing number of chronic kidney disorder cases is a driving force behind the urea cycle disorders treatment market's growth.

A product innovation has emerged as a notable trend, with major companies focusing on creating innovative products to strengthen their market positions. For example, in September 2022, Medunik USA introduced Pheburane oral pellets, a unique and flavor-masking formulation of sodium phenylbutyrate (NaPB) for the long-term management of certain urea cycle disorders. Pheburane, a prescription drug used in conjunction with a specific diet, offers a convenient administration method without the need for mixing. It can be consumed alone or sprinkled on food, enhancing patient compliance.

Major companies in the urea cycle disorder treatment sector are embracing a strategic partnership approach to enhance innovative therapies and improve disease management. Strategic partnerships involve companies utilizing each other's strengths and resources to achieve mutual advantages and success. For example, in June 2024, Orsini Specialty Pharmacy, a US-based provider of personalized care and medications, and Zevra Therapeutics Inc., a US-based company focused on rare disease therapeutics, announced that Orsini will serve as the pharmacy partner for OLPRUVA (sodium phenylbutyrate) oral suspension. OLPRUVA is a prescription medication used alongside specific therapies, including dietary modifications, for the long-term management of urea cycle disorders (UCDs) in particular adult and pediatric patients with deficiencies in carbamylphosphate synthetase (CPS), ornithine transcarbamylase (OTC), or argininosuccinic acid synthetase (AS).

In November 2023, Zevra Therapeutics Inc. acquired Acer Therapeutics Inc. for $91 million, providing Zevra access to rare disease assets, including Edsivo and Olpruva. Edsivo is undergoing Phase III trials for vascular Ehlers-Danlos syndrome, while Olpruva has received FDA approval for certain urea cycle diseases. This acquisition enhances Zevra's market presence and diversifies its revenue stream in the rare disease therapeutics sector. Acer Therapeutics Inc. is a pharmaceutical company offering treatments for urea cycle disorders.

Major companies operating in the urea cycle disorders treatment market include Bausch Health Companies Inc., Recordati Rare Diseases, Eurocept Pharmaceuticals Holding (Lucane Pharma SA), Acer Therapeutics, Ultragenyx Pharmaceutical, Aeglea BioTherapeutics, Arcturus Therapeutics, Inc., Orpharma Pty Ltd., Selecta Biosciences, Inc., Abbott Laboratories, Mead Johnson & Company, LLC, Horizon Therapeutics Plc, Nestle S.A., Danone S.A., Biophone, Relief Therapeutics Holding AG, TheraTriage, Genomatica, Protalix BioTherapeutics, Erytech Pharma, 4D Pharma, Synlogic, Amicus Therapeutics, Sobi, Astellas Pharma Inc., Chiesi Farmaceutici S.p.A., Medpace Holdings, Inc., Celerion, and PTC Therapeutics

North America was the largest region in the urea cycle disorders treatment market in 2024. The regions covered in the urea cycle disorders treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the urea cycle disorders treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The urea cycle disorders treatment market includes revenues earned by entities by hemodialysis, dietary management, and genetic counselling. The market value includes the value of related goods sold by the service provider or included within the service offering. The urea cycle disorders treatment market also includes sales of arginine, sodium phenylacetate, sodium benzoate, and carglumic acid. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Urea Cycle Disorders Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on urea cycle disorders treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for urea cycle disorders treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The urea cycle disorders treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Treatment: Amino Acid Supplements; Sodium Phenylbutyrate; Glycerol Phenylbutyrate; Sodium Benzoate; Other Treatments
• 2) By Enzyme Deficiency: Ornithine Transcarbamylase (OTC); Argininosuccinate Synthetase (AS); Arginase (AG); Argininosuccinate Lyase (AL); Carbamoyl Phosphate Synthase (CPS1)
• 3) By Route of Administration: Oral; Injectables
• 4) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
• Subsegments:
• 1) By Amino Acid Supplements: Arginine Supplements; Citrulline Supplements; Other Essential Amino Acids
• 2) By Sodium Phenylbutyrate: Powder Form; Tablet Form
• 3) By Glycerol Phenylbutyrate: Oral Solutions; Other Forms
• 4) By Sodium Benzoate: Intravenous Solutions; Oral Formulations
• 5) By Other Treatments: Liver Transplantation; Dietary Modifications; Enzyme Replacement Therapy; Other Supportive Therapies
• Companies Mentioned: Bausch Health Companies Inc.; Recordati Rare Diseases; Eurocept Pharmaceuticals Holding (Lucane Pharma SA); Acer Therapeutics; Ultragenyx Pharmaceutical
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Urea Cycle Disorders Treatment Market Characteristics

3. Urea Cycle Disorders Treatment Market Trends And Strategies

4. Urea Cycle Disorders Treatment Market - Macro Economic Scenario including the impact of Interest Rates, Inflation, Geopolitics and Covid And Recovery on the Market

5. Global Urea Cycle Disorders Treatment Growth Analysis And Strategic Analysis Framework

• 5.1. Global Urea Cycle Disorders Treatment PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Urea Cycle Disorders Treatment Market Growth Rate Analysis
• 5.4. Global Urea Cycle Disorders Treatment Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Urea Cycle Disorders Treatment Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Urea Cycle Disorders Treatment Total Addressable Market (TAM)

6. Urea Cycle Disorders Treatment Market Segmentation

• 6.1. Global Urea Cycle Disorders Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Amino Acid Supplements
• Sodium Phenylbutyrate
• Glycerol Phenylbutyrate
• Sodium Benzoate
• Other Treatments
• 6.2. Global Urea Cycle Disorders Treatment Market, Segmentation By Enzyme Deficiency, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Ornithine Transcarbamylase (OTC)
• Argininosuccinate Synthetase (AS)
• Arginase (AG)
• Argininosuccinate Lyase (AL)
• Carbamoyl Phosphate Synthase (CPS1)
• 6.3. Global Urea Cycle Disorders Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Injectables
• 6.4. Global Urea Cycle Disorders Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• 6.5. Global Urea Cycle Disorders Treatment Market, Sub-Segmentation Of Amino Acid Supplements, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Arginine Supplements
• Citrulline Supplements
• Other Essential Amino Acids
• 6.6. Global Urea Cycle Disorders Treatment Market, Sub-Segmentation Of Sodium Phenylbutyrate, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Powder Form
• Tablet Form
• 6.7. Global Urea Cycle Disorders Treatment Market, Sub-Segmentation Of Glycerol Phenylbutyrate, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral Solutions
• Other Forms
• 6.8. Global Urea Cycle Disorders Treatment Market, Sub-Segmentation Of Sodium Benzoate, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Intravenous Solutions
• Oral Formulations
• 6.9. Global Urea Cycle Disorders Treatment Market, Sub-Segmentation Of Other Treatments, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Liver Transplantation
• Dietary Modifications
• Enzyme Replacement Therapy
• Other Supportive Therapies

7. Urea Cycle Disorders Treatment Market Regional And Country Analysis

• 7.1. Global Urea Cycle Disorders Treatment Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Urea Cycle Disorders Treatment Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Urea Cycle Disorders Treatment Market

• 8.1. Asia-Pacific Urea Cycle Disorders Treatment Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Urea Cycle Disorders Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Urea Cycle Disorders Treatment Market, Segmentation By Enzyme Deficiency, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Urea Cycle Disorders Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Urea Cycle Disorders Treatment Market

• 9.1. China Urea Cycle Disorders Treatment Market Overview
• 9.2. China Urea Cycle Disorders Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Urea Cycle Disorders Treatment Market, Segmentation By Enzyme Deficiency, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Urea Cycle Disorders Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Urea Cycle Disorders Treatment Market

• 10.1. India Urea Cycle Disorders Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Urea Cycle Disorders Treatment Market, Segmentation By Enzyme Deficiency, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Urea Cycle Disorders Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Urea Cycle Disorders Treatment Market

• 11.1. Japan Urea Cycle Disorders Treatment Market Overview
• 11.2. Japan Urea Cycle Disorders Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Urea Cycle Disorders Treatment Market, Segmentation By Enzyme Deficiency, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Urea Cycle Disorders Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Urea Cycle Disorders Treatment Market

• 12.1. Australia Urea Cycle Disorders Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Urea Cycle Disorders Treatment Market, Segmentation By Enzyme Deficiency, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Urea Cycle Disorders Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Urea Cycle Disorders Treatment Market

• 13.1. Indonesia Urea Cycle Disorders Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Urea Cycle Disorders Treatment Market, Segmentation By Enzyme Deficiency, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Urea Cycle Disorders Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Urea Cycle Disorders Treatment Market

• 14.1. South Korea Urea Cycle Disorders Treatment Market Overview
• 14.2. South Korea Urea Cycle Disorders Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Urea Cycle Disorders Treatment Market, Segmentation By Enzyme Deficiency, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Urea Cycle Disorders Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Urea Cycle Disorders Treatment Market

• 15.1. Western Europe Urea Cycle Disorders Treatment Market Overview
• 15.2. Western Europe Urea Cycle Disorders Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Urea Cycle Disorders Treatment Market, Segmentation By Enzyme Deficiency, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Urea Cycle Disorders Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Urea Cycle Disorders Treatment Market

• 16.1. UK Urea Cycle Disorders Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Urea Cycle Disorders Treatment Market, Segmentation By Enzyme Deficiency, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Urea Cycle Disorders Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Urea Cycle Disorders Treatment Market

• 17.1. Germany Urea Cycle Disorders Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Urea Cycle Disorders Treatment Market, Segmentation By Enzyme Deficiency, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Urea Cycle Disorders Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Urea Cycle Disorders Treatment Market

• 18.1. France Urea Cycle Disorders Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Urea Cycle Disorders Treatment Market, Segmentation By Enzyme Deficiency, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Urea Cycle Disorders Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Urea Cycle Disorders Treatment Market

• 19.1. Italy Urea Cycle Disorders Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Urea Cycle Disorders Treatment Market, Segmentation By Enzyme Deficiency, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Urea Cycle Disorders Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Urea Cycle Disorders Treatment Market

• 20.1. Spain Urea Cycle Disorders Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Urea Cycle Disorders Treatment Market, Segmentation By Enzyme Deficiency, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Urea Cycle Disorders Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Urea Cycle Disorders Treatment Market

• 21.1. Eastern Europe Urea Cycle Disorders Treatment Market Overview
• 21.2. Eastern Europe Urea Cycle Disorders Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Urea Cycle Disorders Treatment Market, Segmentation By Enzyme Deficiency, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Urea Cycle Disorders Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Urea Cycle Disorders Treatment Market

• 22.1. Russia Urea Cycle Disorders Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Urea Cycle Disorders Treatment Market, Segmentation By Enzyme Deficiency, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Urea Cycle Disorders Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Urea Cycle Disorders Treatment Market

• 23.1. North America Urea Cycle Disorders Treatment Market Overview
• 23.2. North America Urea Cycle Disorders Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Urea Cycle Disorders Treatment Market, Segmentation By Enzyme Deficiency, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Urea Cycle Disorders Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Urea Cycle Disorders Treatment Market

• 24.1. USA Urea Cycle Disorders Treatment Market Overview
• 24.2. USA Urea Cycle Disorders Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Urea Cycle Disorders Treatment Market, Segmentation By Enzyme Deficiency, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Urea Cycle Disorders Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Urea Cycle Disorders Treatment Market

• 25.1. Canada Urea Cycle Disorders Treatment Market Overview
• 25.2. Canada Urea Cycle Disorders Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Urea Cycle Disorders Treatment Market, Segmentation By Enzyme Deficiency, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Urea Cycle Disorders Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Urea Cycle Disorders Treatment Market

• 26.1. South America Urea Cycle Disorders Treatment Market Overview
• 26.2. South America Urea Cycle Disorders Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Urea Cycle Disorders Treatment Market, Segmentation By Enzyme Deficiency, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Urea Cycle Disorders Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Urea Cycle Disorders Treatment Market

• 27.1. Brazil Urea Cycle Disorders Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Urea Cycle Disorders Treatment Market, Segmentation By Enzyme Deficiency, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Urea Cycle Disorders Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Urea Cycle Disorders Treatment Market

• 28.1. Middle East Urea Cycle Disorders Treatment Market Overview
• 28.2. Middle East Urea Cycle Disorders Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Urea Cycle Disorders Treatment Market, Segmentation By Enzyme Deficiency, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Urea Cycle Disorders Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Urea Cycle Disorders Treatment Market

• 29.1. Africa Urea Cycle Disorders Treatment Market Overview
• 29.2. Africa Urea Cycle Disorders Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Urea Cycle Disorders Treatment Market, Segmentation By Enzyme Deficiency, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Urea Cycle Disorders Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Urea Cycle Disorders Treatment Market Competitive Landscape And Company Profiles

• 30.1. Urea Cycle Disorders Treatment Market Competitive Landscape
• 30.2. Urea Cycle Disorders Treatment Market Company Profiles
  • 30.2.1. Bausch Health Companies Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Recordati Rare Diseases Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Eurocept Pharmaceuticals Holding (Lucane Pharma SA) Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Acer Therapeutics Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Ultragenyx Pharmaceutical Overview, Products and Services, Strategy and Financial Analysis

31. Urea Cycle Disorders Treatment Market Other Major And Innovative Companies

• 31.1. Aeglea BioTherapeutics
• 31.2. Arcturus Therapeutics, Inc.
• 31.3. Orpharma Pty Ltd.
• 31.4. Selecta Biosciences, Inc.
• 31.5. Abbott Laboratories
• 31.6. Mead Johnson & Company, LLC
• 31.7. Horizon Therapeutics Plc
• 31.8. Nestle S.A.
• 31.9. Danone S.A.
• 31.10. Biophone
• 31.11. Relief Therapeutics Holding AG
• 31.12. TheraTriage
• 31.13. Genomatica
• 31.14. Protalix BioTherapeutics
• 31.15. Erytech Pharma

32. Global Urea Cycle Disorders Treatment Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Urea Cycle Disorders Treatment Market

34. Recent Developments In The Urea Cycle Disorders Treatment Market

35. Urea Cycle Disorders Treatment Market High Potential Countries, Segments and Strategies

• 35.1 Urea Cycle Disorders Treatment Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Urea Cycle Disorders Treatment Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Urea Cycle Disorders Treatment Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer